sur INVENTIVA (EPA:IVA)
Inventiva Reports Preliminary 2024 First-Half Financial Information
Inventiva, a clinical-stage biopharmaceutical company, disclosed its preliminary financial results for the first half of 2024. As of June 30, 2024, cash and cash equivalents stood at €10.1 million, a significant decline from €26.9 million at the end of 2023. The company issued royalty certificates worth €20.1 million to investors in July, including Samsara BioCapital and existing shareholders.
No revenues were recorded in H1 2024, contrasting with €1.9 million in the same period of 2023. This decline is attributed to the absence of milestone payments like those received in 2023. R&D expenses decreased by 10% to €48.7 million, largely due to a temporary suspension of patient recruitment in its NATiV3 Phase III trial.
The company faces substantial doubt regarding its ability to continue operations beyond September 2024 without securing additional funds. Inventiva is actively exploring various financing options to support its ongoing and future activities.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA